In this chapter, the authors are going to describe the reason why we propose to administer the boost with a single dose of HDR brachytherapy: first, it is an excellent way to escalate the dose, and second it is a very accurate and sure method.
We are going to comment about different authors that are using single-dose boost or several fraction boost and the advantages and withdrawals of both. The main advantage is that we only need one surgical procedure for needle insertion, and thus movement between fractions can be avoided. And it can be done in real-time administering the brachytherapy in the operating theatre.
We are going to discuss about dose equivalence to normofractionation using alpha-beta model. And last, we are going to describe our technique in detail and our institution’s result.
This is a preview of subscription content, log in to check access.
Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(2):316–27.CrossRefPubMedGoogle Scholar
Vargas CE, Martinez AA, al BTP e. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys. 2006;66(2):416–23.CrossRefPubMedGoogle Scholar
Al-Mamgani A, van Putten WLJ, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–8.CrossRefPubMedGoogle Scholar
Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–87.CrossRefPubMedGoogle Scholar
Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74.CrossRefPubMedGoogle Scholar
Peeters STH, Heemsbergen WD, van Putten WLJ, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–34.CrossRefPubMedGoogle Scholar
Pistis F, Guedea F, Pera J, et al. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy. 2010;9(1):15–22.CrossRefPubMedGoogle Scholar
Boladeras A, Santorsa L, Gutierrez C, et al. External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer. Radiother Oncol. 2014;112(2):227–32.CrossRefPubMedGoogle Scholar
Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103:217–22.CrossRefPubMedGoogle Scholar
Agoston P, Major T, Fröhlich G, et al. Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. Brachytherapy. 2011;10:376–84.CrossRefPubMedGoogle Scholar
Galalae RM, Martinez A, Nuernberg N, et al. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol. 2006;182:135–41.CrossRefPubMedGoogle Scholar
Galalae RM, Zakikhany NH, Geiger F, et al. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer-a benchmark for high-tech external beam radiotherapy alone? Brachytherapy. 2014;13:117–22.CrossRefPubMedGoogle Scholar
Martinez AA, Gonzalez J, Ye H, et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:363–70.CrossRefPubMedGoogle Scholar
Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of three dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006;5:157–64.CrossRefPubMedGoogle Scholar
Morton G, Loblaw A, Cheung P, et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol. 2011;100:463–7.CrossRefPubMedGoogle Scholar
Hoskin PJ, Bownes PJ, Ostler P, et al. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol. 2003;68:285–8.CrossRefPubMedGoogle Scholar
Fatyga M, Williamson JF, Dogan N, et al. A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study. Med Phys. 2009;36:3995–4006.CrossRefPubMedPubMedCentralGoogle Scholar
Proust-Lima C, Taylor JMG, Sécher S, et al. Confirmation of a low a/b ratio for prostate cancer treated by external beam radiation therapy alone using a posttreatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys. 2011;79:195–201.CrossRefPubMedGoogle Scholar